<?xml version="1.0" encoding="UTF-8"?>
<ref id="CIT0016">
 <label>16.</label>
 <mixed-citation publication-type="journal">
  <string-name>
   <surname>Sulkowski</surname>
   <given-names>M</given-names>
  </string-name>, 
  <string-name>
   <surname>Hezode</surname>
   <given-names>C</given-names>
  </string-name>, 
  <string-name>
   <surname>Gerstoft</surname>
   <given-names>J</given-names>
  </string-name>, et al. 
  <article-title>Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial</article-title>. 
  <source>
   <italic toggle="yes">Lancet (London, England)</italic>
  </source>. 
  <year>2015</year>;
  <volume>385</volume>(
  <issue>9973</issue>):
  <fpage>1087</fpage>â€“
  <lpage>1097</lpage>. doi:
  <pub-id pub-id-type="doi">10.1016/S0140-6736(14)61793-1</pub-id>
 </mixed-citation>
</ref>
